Noom’s Post

𝐅𝐃𝐀 𝐀𝐩𝐩𝐫𝐨𝐯𝐞𝐬 𝐄𝐱𝐩𝐚𝐧𝐝𝐞𝐝 𝐋𝐚𝐛𝐞𝐥𝐬 𝐟𝐨𝐫 𝐍𝐄𝐗𝐋𝐄𝐓𝐎𝐋® 𝐚𝐧𝐝 𝐍𝐄𝐗𝐋𝐈𝐙𝐄𝐓® Esperion (NASDAQ: ESPR) Esperion announced FDA approval for broad label expansions of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets. The approvals are based on positive CLEAR Outcomes data, allowing for indications in both primary and secondary prevention patients. The enhanced labels support the use of NEXLETOL and NEXLIZET either alone or in combination with statins, with indications for primary hyperlipidemia. These drugs are now available for primary prevention patients, eliminating the statin use requirement. The pending label expansions in Europe are on track, with a positive opinion from the CHMP received on March 21, 2024. The U.S. approvals were based on data from the CLEAR Outcomes trial, demonstrating reductions in LDL-C and cardiovascular risk. Indication Highlights: NEXLIZET and NEXLETOL are indicated to reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy. As an adjunct to diet, NEXLIZET and NEXLETOL are indicated to reduce LDL-C in adults with primary hyperlipidemia, including HeFH. #CholesterolManagement #FDAApproval #CardiovascularHealth #Esperion #NEXLETOL #NEXLIZET #PrimaryPrevention #SecondaryPrevention #PatientCare #Hyperlipidemia #HeartDiseasePrevention

Explore key takeaways from day two of #Asembia24. Tuesday’s sessions covered specialty pharmacy trends, cost and medication accessibility issues, and the impact of policies on the patient journey. Don't miss out on the insights! Read now: go.covermymeds.com/kxn.

🌟 Understanding Drug Interactions: Plavix and Prilosec 🌟 As healthcare professionals, it's crucial to be aware of the interactions between commonly prescribed medications. One significant interaction involves Plavix (clopidogrel) and Prilosec (omeprazole). Plavix is an antiplatelet medication used to reduce the risk of heart attack and stroke, while Prilosec is a proton pump inhibitor that helps manage acid reflux and prevent stomach ulcers. However, co-administration of these two can diminish the effectiveness of Plavix, potentially increasing the risk of cardiovascular events. It's essential for healthcare providers to evaluate the necessity of each medication and consider alternative options or strategies to mitigate this interaction. Continuous education and open communication with patients about their medication regimens can lead to better health outcomes. Let's prioritize patient safety by staying informed about drug interactions! #Pharmacy #PatientSafety #Healthcare #Cardiology #Pharmacology

Prescribing generic specialty medications for #MultipleSclerosis (MS) presents challenges, notably in ensuring medication quality and efficacy. A significant concern is the variability in the quality of #generic medications, as highlighted by the International Journal of MS Care. They reported a case where a patient experienced a severe exacerbation after being switched to a generic version of #teriflunomide, which was found to be substandard. This underscores the importance of careful consideration and monitoring when prescribing generics to ensure patient safety and treatment effectiveness. How can we as #pharmacists and MS specialists contribute to patients safety and medication effectiveness ⁉️ #patientsafety #TheMSPharmacist #specialtypharmacy

OTC proton pump inhibitors (PPIs), highlighting their dual role in providing convenient relief for acid-related issues while also posing risks of overuse and potential long-term side effects. This underscores the importance of balancing accessibility with proper usage guidance. As healthcare professionals, it's crucial to promote informed decisions through patient education to maximize benefits and minimize risks. https://lnkd.in/gtg2rf3T

Interesting to see #subcutaenous #ocrevus making progress towards market entry. With an #EMA decision in the near future, could the #US be far behind? Also, once it is approved, what will happen to #Kesimpta, #Briumvi, and even IV Ocrevus? IV Ocrevus is already approved for home infusion, so 10 minutes (q6months) in a patient's home for the SQ version could really raise the profile (with #multiplesclerosis #patients) for an already successful therapy. https://lnkd.in/eJ7qH3ZS

GLP-1 agonists are traditionally offered as injectables, but that may limit some patients' abilities to benefit from this type of medication gaining notoriety for its benefits in #weightmanagement and #obesity. We work closely with pharmacists, health care providers, and researchers to find where innovation can improve patient care and access to essential medications like these #GLP1agonists. We're proud to announce that we have a new sublingual base that is specifically designed to deliver high molecular weight medications like #semaglutide without an injection. https://lnkd.in/gDPP5biM #daytonoh #ohiopharmacy #huberheights #compoundingpharmacy #pharmaceuticalinnovation

“During operations, the #Impella device could cut through the wall of the left ventricle,” the company’s notice stated. “The use of the affected Impella pumps may cause serious adverse health consequences, including left ventricle perforation or free wall rupture, hypertension, lack of blood flow, and death.” #regulatoryaffairs #medicaldevices #cardiology #interventionalcardiology #DGK2024 is just around the corner so I expect the on-site Abiomed team to be grilled about this... To be fair, though, Impella pumps are often used in the most severe of cases, where patients often do not have guaranteed survival, and the complications appear to be relatively (49 cases of death vs. 66,000 devices recalled), but this does go to show... an abundance of caution is the bare minimum. via Dr. Mohammad Intakhab Alam https://lnkd.in/e7agy4YC

#Ozempic and #Rybelsus are both FDA-approved for #type2diabetes not #obesity, but both cause #weightloss. What is the #difference? Heidi Borst from Forbes interviewed our Chief Medical Officer, Leon Igel, MD, FACP, FTOS, DABOM about the two #medications. You can read the article here to learn more. Thanks Julianne Roseman and Plug and Play. Intellihealth https://lnkd.in/e5xXJyTD

November is COPD Awareness Month, a time to highlight advancements in managing Chronic Obstructive Pulmonary Disease (COPD). Recent developments include: • Pharmacological Innovations: Triple therapy inhalers combining LABA, LAMA, and ICS have enhanced lung function and quality of life. Biologics and phosphodiesterase-4 inhibitors like roflumilast offer additional benefits for specific patient groups. • Non-Pharmacological Approaches: Pulmonary rehabilitation, oxygen therapy, and surgical interventions such as lung volume reduction surgery (LVRS) and lung transplantation play crucial roles in comprehensive COPD care. • Personalized Care Plans: Tailoring treatment to individual needs, incorporating regular monitoring, patient education, and self-management strategies, is essential for effective COPD management. Digital Health Tools: Telemedicine platforms and mobile apps facilitate remote monitoring and enhance patient engagement, ensuring continuity of care. At eNavvi, we are committed to supporting healthcare providers in delivering optimal care. Our platform offers real-time medication pricing across pharmacies, enabling patients to save up to 82% on drug costs. By providing transparent and affordable medication options, eNavvi empowers practices to offer comprehensive patient support. Learn more about how eNavvi.com can enhance your practice and improve patient outcomes. #healthcare #healthcaretech #healthcarestartup #healthcareinnovation #copd #copdawareness